Evidence map›Paper›PMID 38507452›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Orphan lysosomal solute carrier MFSD1 facilitates highly selective dipeptide transport.

Danila Boytsov, Gregor M Madej, Georg Horn, Nadine Blaha, Thomas Köcher, Harald H Sitte, Daria Siekhaus, Christine Ziegler, Walter Sandtner, Marko Roblek

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Danila BoytsovInstitute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna AT-1090, Austria.ORCID 0000-0002-6200-7158
Gregor M MadejDepartment of Biophysics II/Structural Biology, University of Regensburg, Regensburg DE-93053, Germany.ORCID 0000-0001-9181-6387
Georg HornDepartment of Biophysics II/Structural Biology, University of Regensburg, Regensburg DE-93053, Germany.
Nadine BlahaVienna BioCenter Core Facilities, Metabolomics, Vienna BioCenter, Vienna AT-1030, Austria.
Thomas KöcherVienna BioCenter Core Facilities, Metabolomics, Vienna BioCenter, Vienna AT-1030, Austria.
Harald H SitteInstitute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna AT-1090, Austria.ORCID 0000-0002-1339-7444
Daria Siekhaus *Institute of Science and Technology Austria, Klosterneuburg AT-3400, Austria.ORCID 0000-0001-8323-8353
Christine Ziegler *Department of Biophysics II/Structural Biology, University of Regensburg, Regensburg DE-93053, Germany.
Walter Sandtner *Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna AT-1090, Austria.ORCID 0000-0003-3637-260X
Marko RoblekInstitute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna AT-1090, Austria.ORCID 0000-0001-9588-1389
University of Regensburg · DEInstitute of Science and Technology Austria · ATMedical University of Vienna · ATVienna Biocenter · ATAl-Ahliyya Amman University · JO

Funding

Austrian Science Fund (FWF) P 36621-BAustrian Science Fund (FWF) P 36667Institute of Science and Technology Austria (ISTA) core funding
6 · The paper itself

Abstract

Orphan solute carrier (SLC) represents a group of membrane transporters whose exact functions and substrate specificities are not known. Elucidating the function and regulation of orphan SLC transporters is not only crucial for advancing our knowledge of cellular and molecular biology but can potentially lead to the development of new therapeutic strategies. Here, we provide evidence for the biological function of a ubiquitous orphan lysosomal SLC, the Major Facilitator Superfamily Domain-containing Protein 1 (MFSD1), which has remained phylogenetically unassigned. Targeted metabolomics revealed that dipeptides containing either lysine or arginine residues accumulate in lysosomes of cells lacking MFSD1. Whole-cell patch-clamp electrophysiological recordings of HEK293-cells expressing MFSD1 on the cell surface displayed transport affinities for positively charged dipeptides in the lower mM range, while dipeptides that carry a negative net charge were not transported. This was also true for single amino acids and tripeptides, which MFSD1 failed to transport. Our results identify MFSD1 as a highly selective lysosomal lysine/arginine/histidine-containing dipeptide exporter, which functions as a uniporter.

Indexed as

LysineMembrane Transport ProteinsArginineBiological TransportDipeptidesHEK293 CellsHumansLysosomesPhosphoproteinsArginineDipeptidesLysineMembrane Transport ProteinsNIBAN2 protein, humanPhosphoproteinsdeorphanization of SLC MFSD1dipeptideselectrophysiologylysosomestargeted metabolomics

Identifiers

PMID38507452
PMCPMC10990142
OpenAlexW4392983259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.